Alembic Pharma has reported a Q1 net profit of INR 121 crore, up from a net loss of INR 66 crore YoY, led by increased sales growth across its segments. The Indian branded business recorded a 9% YoY growth to INR 524 crore, while US generics saw 6% YoY growth to INR 354 crore.
Related Keywords
India , Pranav Amin , , Alembic Pharma , Neoplasm , Alembic Pharma Share Price , Alembic Pharma Shares , Markets News ,
comparemela.com © 2020. All Rights Reserved.